Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 1 2Phase 2 1

Status

Terminated 7Completed 6Active not recruiting 4Recruiting 3

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Thoracic 6Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Neoplasm Metastasis 3Triple Negative Breast Neoplasms 1Lung Neoplasms 1Carcinoma 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Terminated × Interventional × canakinumab × Clear all
NCT03631199 2026-02-25

CANOPY-1

Novartis

Phase 3 Terminated
673 enrolled 38 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03742349 2025-05-18

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Novartis

Phase 1 Terminated
64 enrolled
Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03447769 2024-10-09

Canopy-A

Novartis

Phase 3 Terminated
1,382 enrolled 23 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03968419 2024-06-20

CANOPY-N

Novartis

Phase 2 Terminated
88 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03626545 2023-08-21

CANOPY-2

Novartis

Phase 3 Terminated
245 enrolled 29 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05725343 2023-02-13

CANAL

Mario Negri Institute for Pharmacological Research

Phase 3 Terminated
350 enrolled
Thoracic

Lung Neoplasms

NCT03064854 2022-08-15

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Novartis

Phase 1 Terminated
111 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡